MICHAEL COLLINS: Open Payments
NPI 1619069648 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,847 in 152 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $814 · 2025 $3,847
Food & beverage: $3,775Education: $71
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 28 | $783 |
| Vanda Pharmaceuticals Inc. | 11 | $440 |
| Alkermes, Inc. | 21 | $387 |
| E.R. Squibb & Sons, L.L.C. | 15 | $356 |
| Teva Pharmaceuticals USA, Inc. | 12 | $320 |
| Indivior Inc. | 15 | $316 |
| Axsome Therapeutics, Inc. | 10 | $296 |
| Neurocrine BioSciences, Inc. | 14 | $280 |
| Otsuka America Pharmaceutical, Inc. | 7 | $217 |
| ABBVIE INC. | 10 | $180 |
Products named: INVEGA SUSTENNA, FANAPT, COBENFY, SUBLOCADE, Auvelity, INGREZZA, ARISTADA, UZEDY.
Industry payments across OK — which companies pay providers there.
